Stockscreener 앱 받기
14.29
1.28%
0.18
시간 외 거래:
13.29
-1.00
-7.00%
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics (SMMT) Launches $500M Public Offering Amid S - GuruFocus
Summit Therapeutics launches $500 million stock offering By Investing.com - Investing.com South Africa
Summit Therapeutics launches $500 million stock offering - Investing.com
Summit Therapeutics files for $500M common stock offering; shares slide over 9% - MSN
Summit Therapeutics Launches $500 Million Common Stock Public Offering - Moomoo
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Australia
Summit Therapeutics stock tumbles on $500M stock offering By Investing.com - Investing.com Canada
Summit Therapeutics stock tumbles on $500M stock offering - Investing.com India
Summit Therapeutics Announces Proposed Public Offering Of Common Stock - TradingView
Summit Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire
Summit Therapeutics (NASDAQ: SMMT) files shelf to offer common, preferred, debt - Stock Titan
Discipline and Rules-Based Execution in SMMT Response - Stock Traders Daily
Summit Therapeutics plc (SMMT) stock price, news, quote and history - Yahoo Finance UK
Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock - Yahoo Finance
5 Best Large Cap Stocks Under $30 With Highest Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data - Insider Monkey
All you need to know about Summit Therapeutics (SMMT) rating upgrade to buy - MSN
Summit falls despite Phase 3 ivonescimab data in NSCLC - MSN
Insider Buying: Manmeet Soni Acquires 50,000 Shares of Summit Th - GuruFocus
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock By Investing.com - Investing.com Nigeria
Summit Therapeutics COO & CFO Soni buys $722,250 in stock - Investing.com UK
Summit Therapeutics COO & CFO Soni buys $722,250 in stock By Investing.com - Investing.com South Africa
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock - Investing.com
Summit Therapeutics (SMMT) Co‑CEO associated trust purchases 100,000 shares at $14.60 - Stock Titan
Summit Therapeutics (SMMT) co-CEO buys 100K shares via revocable trust - Stock Titan
Summit Therapeutics Insider Bought Shares Worth $722,250, According to a Recent SEC Filing - marketscreener.com
Summit Therapeutics COO, CFO Purchased Shares Worth Over $722K - TradingView
Executive Manmeet Singh Soni buys 50K Summit Therapeutics (SMMT) shares - Stock Titan
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy - Yahoo Finance
Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC - Insider Monkey
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology CongressSlideshow (NASDAQ:SMMT) 2026-06-03 - Seeking Alpha
Summit Therapeutics Enables Affiliate and Insider Share Purchases - TipRanks
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics directors, executives likely to buy shares under ATM program - TradingView
Summit Therapeutics (SMMT) leaders may buy shares via existing ATM - Stock Titan
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT) - The Globe and Mail
Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments - Insider Monkey
Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic - Insider Monkey
Summit Therapeutics (SMMT) Shares Drop Despite Positive Cancer T - GuruFocus
Exclusive BAC Article: Akeso And Summit: Positive China HARMONi-6 Trial Ivonescimab Squamous NSCLC, HARMONi-3 Data From Summit 2nd Half 2026 & 1st Half 2027, And Catalysts (OTCMKTS:AKESF) - Seeking Alpha
Summit Therapeutics (SMMT) Slides As Bearish Calls Mount - StocksToTrade
Summit Therapeutics Inc. (SMMT) once dropped over 12.8%, approaching the May 1st low of $15.14. - Bitget
Summit Therapeutics Reports Promising Phase II Ivonescimab Results in Metastatic Colorectal Cancer at ASCO 2026 - Minichart
1.97%
0.97%
자본화:
|
볼륨(24시간):